Newly developed PSG score improves patient selection for PSMA radiopharmaceutical therapy
A newly established PSMA PET scoring system can successfully predict whether metastatic castration-resistant prostate cancer (mCRPC) patients will respond to treatment with 177Lu-PSMA therapy. International, multicenter testing ...
Apr 19, 2023
0
6